Table 2.
Micro-RNAs as Non-invasive Biomarkers in Blood Samples
| Cancer | Samples | Diagnostic miRs | Prognostic miRs | References |
|---|---|---|---|---|
| Head and Neck | Plasma | miR-184 (up) | [90] | |
| Squamous cell carcinoma | Plasma | miR-24 (up) | [91] | |
| Plasma | miR-31 (up) | [92] | ||
| Plasma | miR-181 (up) | miR-181 (up) correlated with poor survival, lymph-node metastasis, and vascular invasion | [93] | |
| Breast cancer | Serum | miR-155 (up) in PR+ve patients | [68] | |
| Plasma |
miR-425*(up); let-7d*(down) |
[94] | ||
| Serum | miR-10b, -34a, -155 (up) | miR-10b, -34a, -155 (up) correlated with metastasis | [95] | |
| Serum | miR -21, -106a, -155 (up); miR-126, -199a, -335 (down) | [96] | ||
| Whole blood | miR-195 (up) | miR-21, -10b (up) in ER -ve patients; let-7a (down) in lymph node +ve patients | [97] | |
| Serum | miR-21 (up) correlated with visceral metastasis | [98] | ||
| Non-small-cell lung carcinoma | Pooled serum | miR-25, -223 (up) | [99] | |
| Exosome from plasma | miR-17-3p, -21, -106a, -146, -155, -191, -192, -203, -205, -210, -212, -214 (up) | [58] | ||
| Pooled serum | miR-486, -30d (up); miR-1, -499 (down) associated with overall survival | [100] | ||
| Serum | miR-10b, -155 (up) | miR-10b (up) associated with lymph node metastasis | [101] | |
| Vesicles of plasma samples | let-7d, let-7f, miR-223, -383, -192, -30e-5p, -301, -572, -20b, -345 (down) | let-7f, miR-30e-3p (up) associated with poor outcome | [59] | |
| Gastrointestinal Cancers | ||||
| Colorectal cancer | Plasma | miR-17-3p, -92 (up) | [102] | |
| Plasma | miR-29a, -92a (up) | [103] | ||
| Plasma | miR-221 (up) | miR-221 (up) associated with poor overall survival | [104] | |
| Esophageal | Serum | miR-10a, -22, -100, -148b, -223, -133a, -127-3p (up) | [105] | |
| Gastric cancer | Serum | miR-1, -20a, -27a, -34, -423-5p (up) | miR-1, -20a, -27a, -34, -423-5p (up) | [106] |
| Plasma | miR-17-5p, -21, -106a, -106b (up); let-7a (down) | [107] | ||
| Hepatocellu-lar carcinoma | Serum | miR-500 (up) | [108] | |
| Serum | miR-1, -25, -92a, -206, -375, -let-7f (up) (HBV-associated); miR-25, -375, and let-7f (up) (HCC detection) | [109] | ||
| Serum | miR-21, -122, -223 (up) | [110] | ||
| Serum | miR-122 (up) | [111] | ||
| Serum | miR-885-5p (up) | [112] | ||
| Serum | miR-16 (down) combined with AFP, AFP DCP increases specificity of HCC detection | [113] | ||
| Pancreatic cancer | Plasma | miR-21, -210, -155, -196a (up) | [63] | |
| Plasma | miR-210 (up) | [62] | ||
| Plasma | miR-21 (up) | [60] | ||
| Serum | miR-21, -155, -196a (up) | miR-196a (up) | [61] | |
| Ovarian cancer | Exosome from serum | miR-21, -141, -200a, -200c, -200b, -203, -205, -214 (up) correlated with stage | miR-21, -141, -200a, -200c, -200b, -203, -205, -214 (up) correlated with stage | [57] |
| Serum | miR-21, -92, -93, -126 -29a (up); miR-155, -127, -99b (down) | [64] | ||
| Whole blood | miR-30c1* (up); miR -342-3p, -181a*, -450b-5p (down) | [114] | ||
| Prostate cancer | Serum | miR-141 (up) | miR-100, -125b, -141, -143, -296 (up) | [54] |
| Serum | miR-16, -92a, -103, -107, -197, -34b, -328, -485-3p, -486-5p, -92b, -574-3p, -636, -640, -766, -885-5p (up) | [115] | ||
| Serum | miR-20b, -874, -1274a, -1207-5p, -93, -106a (up); miR- 223, -26b, -30c, -24 (down) | miR-24 (down) in metastatic cancers | [116] | |
| Serum | miR-375, -141 (up) | miR-375, -141 (up) | [117] | |
| Serum | miR-21 (up) | miR-21 (up) associated with resistant to docetaxel-based chemotherapy | [118] | |
| Serum | miR-21, -141, -221 (up) | miR-21, -141, -221 (up) | [119] | |